Vimian Group posts 11% organic growth in third quarter

Vimian Group AB reported third quarter revenue of EUR 120.3 million, representing a 15% year-over-year increase, the company said. Organic growth reached 11% for the period.

The MedTech division led performance with EUR 43.2 million in revenue, up 16% year-over-year, and organic growth of 15%. The segment recorded double-digit growth in both dental and orthopedics, with North American orthopedics returning to growth.

Diagnostics generated EUR 7.4 million in revenue, a 44% year-over-year increase, with organic growth of 13%. Veterinary Services posted EUR 19.3 million in revenue, up 22% year-over-year, with 10% organic growth.

Specialty Pharma recorded EUR 50.3 million in revenue, a 9% year-over-year increase, with 7% organic growth. The division faced difficult comparisons due to prior-year US sales campaigns. Excluding these campaigns, organic growth reached 11%.

Adjusted EBITA totaled EUR 29.2 million, up 14% year-over-year, with a margin of 24.3%. Specialty Pharma achieved a margin of 30.3%, while Veterinary Services posted a 30.5% margin.

MedTech’s margin reached 24.4%, and Diagnostics reported a 7.2% margin. Investment in companion animal diagnostics affected the Diagnostics margin.